Veenat Capsule - 100mg Imatinib Mesylate | Targeted Treatment For Philadelphia Chromosome Positive Chronic Myeloid Leukemia (Cml) With Expert Medical Guidance

Loaded with vast industrial knowledge and expertise, we have emerged as a major Exporter & Distributor of Veenat Capsule in New Delhi, Delhi, India.

Each capsule contains Imatinib Mesylate equivalent to Imatinib 100mg.

matinib Mesylate is a protein - tyrosine kinase inhibitor that inhibits the Bcr-Abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia Chromosome abnormality in Chronic Myeloid Leukemia (CML).

Indications:
VEENAT (Imatinib Mesylate) is indicated for the treatment of patients with Philadelphia Chromosome positive Chronic Myeloid Leukemia (CML) in blast crisis, accelerated phase, or in chronic phase.

Dosage & Usage:
Therapy should be initiated under experienced medical guidance in the treatment of patient with Chronic Myeloid Leukemia (CML).
The prescribed dose should be administered orally, with a meal and a large glass of water. Doses of 400mg under chronic phase & 600mg under accelerated phase should be administered once daily or as prescribed by your doctor.

Side Effects:
Some common side effects that may occur as a result of the usage of Veenat, include - nausea, vomiting, diarrhea, muscle cramps. If these symptoms persist or worsen, contact your doctor immediately.

Note:
Veenat is a prescription drug and should be used under proper medical guidance and advice..